title: Response to comment on Edelman et al. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care 2014;37:2132-2140.
authors.affiliation: Department of Medicine, University of California, San Diego, La Jolla, CA sedelman@ucsd.edu.
authors.forename: Steve V
authors.initials: SV
authors.lastname: Edelman
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Rong
authors.initials: R
authors.lastname: Liu
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Jennal
authors.initials: J
authors.lastname: Johnson
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Leonard C
authors.initials: LC
authors.lastname: Glass
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D061268:Insulin Lispro / Q000008:administration & dosage*; D049528:Insulin, Long-Acting / Q000008:administration & dosage*; D008297:Male
chemical_list: D007004:Hypoglycemic Agents; D061268:Insulin Lispro; D049528:Insulin, Long-Acting